citalopram / Generic mfg. - LARVOL DELTA

Design of a sodium polyacrylate/carboxymethyl-chitosan-based imprinted cryogel for fluoxetine adsorption in continuous mode. (PubMed, Chemosphere) - "Fluoxetine (FLX) contamination in aquatic environments poses significant ecological risks, highlighting the need for efficient and selective removal technologies. Competitive adsorption with citalopram confirmed the selective recognition of FLX by MIC/NaPA-CMCs, yielding higher FLX uptake and a relative selectivity coefficient (K' > 1) than the non-imprinted cryogel. These results demonstrate the potential of the developed imprinted cryogel for selective FLX removal under continuous-flow conditions."

Journal

LYMPHODEP: Precision Psychiatry for Depression: Immune Response and Affective Symptoms as Predictors of Response to Antidepressants (clinicaltrials.gov) - P=N/A | N=50 | Completed | Sponsor: Germans Trias i Pujol Hospital | Trial completion date: Jul 2027 ➔ Jul 2026 | Trial primary completion date: Dec 2026 ➔ Jun 2026 | Not yet recruiting ➔ Completed

Trial completion • Trial completion date • Trial primary completion date • CNS Disorders • Depression • Inflammation • Mood Disorders • Psychiatry

Citalopram and the Risk of Serious Adverse Events (clinicaltrials.gov) - P=N/A | N=7110 | Active, not recruiting | Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed ➔ Active, not recruiting | Trial completion date: Jan 2026 ➔ Dec 2027

Adverse events • Enrollment closed • Serious adverse event • Trial completion date • Chronic Kidney Disease • Nephrology • Renal Disease

One Health prescribing - development of enantioselective liquid chromatography - tandem mass spectrometry methods to inform chiral switch of prescription pharmaceuticals. (PubMed, Anal Methods) - "Application of the methodology to wastewater samples revealed several analytes were in non-racemic composition including citalopram, fluoxetine, mirtazapine, desmethylmirtazapine, and ritalinic acid. Furthermore, to the best of our knowledge this is the first study to report the enantiomeric composition of baclofen, amlodipine, hydroxyatenolol and ritalinic acid in wastewater. Further application of these newly developed methods can help develop more accurate environmental risk assessments of pharmaceutical enantiomers to inform the proposed chiral switch decision making process in healthcare."

Journal

The menopause after cancer study: A multimodal technology assisted intervention for the management of menopausal symptoms after cancer. (ASCO 2023) - P2 | "The intervention consisted of: (1) use of non-hormonal pharmacotherapy to manage VMS (citalopram for predominantly daytime VMS and/or gabapentin for predominantly nocturnal VMS) (2) digital cognitive behavioural therapy for insomnia using Sleepio (BigHealth), (3) self-management strategies for VMS delivered via a mobile application called myPatientSpace and (4) nomination of an additional support person/partner. The MAC study demonstrates that improvements in QoL can be achieved using this multimodal intervention to target VMS and insomnia after cancer. Clinical trial information: NCT04766229."

Breast Cancer • CNS Disorders • Insomnia • Oncology • Sleep Disorder • Solid Tumor

Long-Term Tapentadol Use for Neuropathic Pain in a Hemodialysis Patient with End-stage Renal Disease: A Case Report. (PubMed, Pain Med Case Rep) - "This case suggests long-term tapentadol may be a safe and effective pain management option in selected patients with end-stage renal disease on hemodialysis, though further study is needed."

Journal • Chronic Kidney Disease • Nephrology • Neuralgia • Pain • Renal Disease

Association between antidepressant use and the risk of type 2 diabetes: a multi-stage Mendelian randomization study. (PubMed, Eur Arch Psychiatry Clin Neurosci) - "This study provides genetic evidence suggesting medication-specific associations between antidepressant use liability and T2D susceptibility. Although the observed effect sizes were modest, these results highlight that the metabolic effects of individual antidepressants may vary, thus, warranting further studies to determine the clinical relevance of our findings."

Journal • CNS Disorders • Depression • Diabetes • Metabolic Disorders • Psychiatry • Type 2 Diabetes Mellitus

SSRI Use in Irritable Bowel Syndrome and Its Impact on Disease Outcomes: A Propensity-Matched Real-World Cohort Study (ACG 2026) - "Cohort 1 received an SSRI (sertraline, escitalopram, citalopram, fluoxetine, or paroxetine) within 1 year of diagnosis without concurrent TCA use. Post-matching cohorts were well-balanced (79.7% female, ~80% White). SSRI use was associated with lower functional symptom persistence (57.0% vs. 60.7%; RR 0.94, 95% CI 0.93-0.94; p< 0.001; median time-to-recurrence 589 vs."

Clinical • Real-world • Real-world evidence • CNS Disorders • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Mood Disorders • Ulcerative Colitis

Antidepressant Prescribing Trends for Adults With and Without Autism in the United Kingdom From 1997 to 2023: A Population-Based Cohort Study Using Clinical Practice Research Datalink Aurum. (PubMed, Autism Res) - "In each calendar year we calculated: annual, lifetime and new antidepressant prescribing; indications for serotonin-selective reuptake inhibitor initiation; average doses prescribed for citalopram, fluoxetine, and sertraline; and the proportion of courses that lasted over 1, 2, and 3 years. Antidepressant prescribing has increased more for autistic adults than non-autistic adults since 1997, with more new starters, higher doses and longer course durations. This potentially increases the risk of adverse medication effects for autistic adults and emphasizes the need for stronger evidence around the effectiveness and tolerability of mental health interventions and the reasons for systematic differences in prescribing."

Journal • Autism Spectrum Disorder • CNS Disorders • Depression • Developmental Disorders • Genetic Disorders • Mental Retardation • Mood Disorders • Psychiatry

Comparative Efficacy and Safety of Treatments for Parkinson's Disease With Depression: A Systematic Review and Bayesian Model-Based Network Meta-Analysis. (PubMed, Brain Behav) - "Our findings indicate that selective serotonin reuptake inhibitors (SSRIs), dopamine agonists, and rTMS suggest relative efficacy and an acceptable safety profile in treating PD with depression. However, given the limited evidence for several interventions, these findings should be interpreted cautiously and confirmed in larger, multicenter studies."

Clinical • Journal • Retrospective data • Review • CNS Disorders • Depression • Mood Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

A case of generalised pruritus of unknown origin, associated with a paraproteinaemia, treated with citalopram. (PubMed, Clin Exp Dermatol) - No abstract available

Journal • Dermatology • Pruritus

Beyond control in psychiatric research: systematic review and meta-analysis of placebo treatment responses across major psychiatric conditions in citalopram and escitalopram RCTs. (PubMed, Br J Psychiatry) - "This study used a unique approach to examine placebo responses from the same interventions across multiple major psychiatric disorders. We found substantial placebo responses across psychiatric conditions and significant heterogeneity, influenced by a range of study-related and demographic factors. The findings underscore the complexity of placebo responses and highlight the importance of considering these variances in both research design and clinical translation."

Journal • Retrospective data • Review • CNS Disorders • Depression • Mental Retardation • Mood Disorders • Obsessive-Compulsive Disorder • Post-traumatic Stress Disorder • Psychiatry

Effects of psychotropic medications on a placenta cell model: a functional study with BeWo cells. (PubMed, Reprod Toxicol) - "Our findings reveal marked differences in how various medications affected cell viability and hormone production. Whether these effects could be related to changes in clinical outcomes such as birth weight and small-for-gestational-age requires further investigation."

Journal • Small for Gestational Age • LEP

Too Long to QT: A Case of Pneumoperitoneum-Induced Torsades de Pointes (ASA 2026) - "Reinsufflation at 10 mmHg triggered recurrent torsades, treated with additional magnesium, amiodarone (150 mg), and metoprolol (10 mg), and the procedure was aborted. Postoperative evaluation revealed marked baseline QT prolongation (QTc 522 ms) due to chronic citalopram use, compounded by hypomagnesemia following bowel preparation and preoperative metronidazole. This case highlights the synergistic interaction of QT-prolonging medications, perioperative hypomagnesemia, and pneumoperitoneum-induced physiologic stress in precipitating torsades de pointes."

Clinical • Melanoma • Solid Tumor

Citalopram-induced photopigmentation. (PubMed, JAAD Case Rep) - No abstract available

Journal

Improving urban wastewaters using natural microbial communities in bench-scale reactors. (PubMed, Bioresour Technol) - "Fluoxetine and citalopram showed greater removal than other CECs, although variability among treatments was high. The system performance was associated with algal biomass, total organic matter content, and microalgal abundances. These results highlight the experimental approach as a scalable pilot for tertiary treatment in small facilities."

Journal

Large-scale analysis demonstrates the influence of CYP2C19 genotype on specific SSRI side effects. (PubMed, Pharmacogenomics J) - "Among participants taking escitalopram or citalopram, slower metabolizers experienced side effects significantly more often than faster metabolizers (OR = 1.04 per grade, 95%CI = [1.02-1.06] and OR = 1.05 per grade, 95%CI = [1.02-1.07]) and were more likely to discontinue treatment due to side effects (OR = 1.05, 95%CI = [1.03-1.08], e.g. 29.7% of poor vs. 21.6% of ultrarapid metabolizers, and OR = 1.07, 95%CI = [1.04-1.11], e.g. 25.7% vs. 20.2%). Slower metabolizers taking sertraline reported tremor more often than faster metabolizers. Overall, we find substantial differences in side effect risk with different CYP2C19 genotypes, supporting the notion that individuals seeking depression treatment may benefit from pharmacogenetic-guided treatment selection to minimize side effects and reduce discontinuations."

Adverse events • Journal • CNS Disorders • Depression • Movement Disorders • Psychiatry • Sleep Disorder • CYP2C19

Development of erectile dysfunction in men treated for major depressive disorder with selective serotonin reuptake inhibitors: a systematic review. (PubMed, Arch Med Sci) - "SSRIs - fluoxetine, escitalopram, and citalopram - showed a higher risk of ED than other SSRIs. The findings indicated a positive association between SSRIs and SD. However, evidence supporting a strong link between SSRIs and ED was insufficient."

Journal • Review • CNS Disorders • Depression • Erectile Dysfunction • Major Depressive Disorder • Mood Disorders • Psychiatry • Sexual Disorders

Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults With Major Depressive Disorder: A Systematic Review and Network Meta-Analysis. (PubMed, Focus (Am Psychiatr Publ)) - "In head-to-head studies, agomelatine, amitriptyline, escitalopram, mirtazapine, paroxetine, venlafaxine, and vortioxetine were more effective than other antidepressants (range of ORs 1·19-1·96), whereas fluoxetine, fluvoxamine, reboxetine, and trazodone were the least efficacious drugs (0·51-0·84). For acceptability, agomelatine, citalopram, escitalopram, fluoxetine, sertraline, and vortioxetine were more tolerable than other antidepressants (range of ORs 0·43-0·77), whereas amitriptyline, clomipramine, duloxetine, fluvoxamine, reboxetine, trazodone, and venlafaxine had the highest dropout rates (1·30-2·32)...These results should serve evidence-based practice and inform patients, physicians, guideline developers, and policy makers on the relative merits of the different antidepressants. National Institute for Health Research Oxford Health Biomedical Research Centre and the Japan Society for the Promotion of Science.Appeared..."

Journal • Retrospective data • Bipolar Disorder • CNS Disorders • Depression • Major Depressive Disorder • Mental Retardation • Mood Disorders • Psychiatry

Beyond rodents: A systematic review of antidepressant-like effects in Drosophila melanogaster as an alternative model in psychopharmacology. (PubMed, Altern Lab Anim) - "Most studies involved adult flies (k = 131), males (k = 56), fluoxetine treatment (k = 109) and courtship outcomes (k = 85). Some studies involved larvae (k = 15), females (k = 39), treatment with other antidepressants (citalopram, k = 12; desipramine, k = 6; amitriptyline, k = 2; imipramine, k = 2) and other outcomes (locomotion, k = 11; sucrose preference, k = 5; light preference, k = 2; aggression, k = 2; climbing, k = 1)...In addition, incomplete reporting precluded an accurate risk-of-bias assessment. These findings highlight the need for standardisation and transparent reporting, in order to establish flies as a reproducible, ethically acceptable alternative to vertebrates in antidepressant research."

Journal • Preclinical • Review • Psychiatry

Environmental impact of antidepressants: Is a new prescription framework possible? (PubMed, Br J Clin Pharmacol) - "In the future, clinical guidelines could be adjusted to favour first-line substances with lower environmental impact but comparable efficacy, as for citalopram and escitalopram compared with sertraline. Together with strengthened implementation of non-pharmacological strategies, these measures could be an active step in fighting environmental pollution and climate change, increasing global health."

Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

Myasthenia gravis with dysphagia as the first symptom and misdiagnosed as anxiety-depressive state: a case report. (PubMed, Front Immunol) - "Initially misdiagnosed with an anxiety-depressive disorder, she experienced only partial and transient improvement with citalopram...Following the failure of initial immunosuppressive therapy, which included prednisone at 30 mg daily, pyridostigmine at 60 mg three times daily, and azathioprine at 25 mg daily, the patient underwent two cycles (totaling 8 infusions) of the FcRn antagonist efgartigimod...Clinicians should prioritize organic etiologies and perform neostigmine and anti-AChR testing to avoid delayed diagnosis. Furthermore, efgartigimod is effective for refractory bulbar MG, enabling rapid remission and corticosteroid tapering."

Journal • CNS Disorders • Depression • Gastrointestinal Disorder • Immunology • Infectious Disease • Mood Disorders • Myasthenia Gravis • Psychiatry • Respiratory Diseases • Solid Tumor • Thymoma • Thymus Cancer

Evaluating Caenorhabditis elegans as a Toxicity Model for Reuptake Inhibitors. (PubMed, MicroPubl Biol) - "Escitalopram showed greater toxicity than citalopram, duloxetine was more toxic than milnacipran, and desvenlafaxine, but not venlafaxine, produced toxicity. These results suggest that C. elegans cannot replace mammalian testing, but may serve as a rapid and low-cost prescreening model."

Journal

Efficacy of Antidepressants in Treating Functional Abdominal Pain Disorders in Children: A Meta-Analysis of Randomized Controlled Trials. (PubMed, Pediatr Gastroenterol Hepatol Nutr) - "Subgroup analyses assessed the differences according to the antidepressant type (amitriptyline vs. citalopram) and treatment duration (4 weeks vs. 12 weeks). Exploratory subgroup analyses indicated that treatment duration might influence symptom improvement; however, these findings were limited by substantial heterogeneity and the small number of trials available. Additional randomized controlled trials are warranted."

Journal • Retrospective data • Pain • Pediatrics

Distribution of citalopram enantiomers following medication with racemic citalopram - a naturalistic therapeutic drug monitoring study. (PubMed, Eur J Clin Pharmacol) - "The percentage of S-citalopram in plasma during treatment with citalopram increased with patient age and decreased with the time from dose intake. In contrast, sex and dose did not significantly affect the percentage of S-citalopram."

Journal